

Moving Beyond Deficiencies: Normalization Strategies in Hemophilia Care

Written by The Life Science Feed Editorial Team · Published 1 December 2025 · Edited by Mara Voss

KEY TAKEAWAYS

- ° lightbulb
- ° The Pivot: 'Normalization' encourages a shift from bleed prevention alone to facilitating a full and unrestricted life for hemophilia patients.
- ° The Data: Studies show that personalized treatment plans, including prophylaxis and newer therapies, can significantly improve quality of life scores and reduce the impact of hemophilia on daily activities.
- ° The Action: Actively engage patients in shared decision-making, discussing their lifestyle goals and tailoring treatment regimens to accommodate those goals, while managing bleeding risk.

Guideline Context

Major guidelines, such as those from the World Federation of Hemophilia (WFH) and the National Hemophilia Foundation (NHF), already emphasize individualized treatment plans and patient-centered care. However, the 'normalization' concept takes this a step further by explicitly focusing on achieving a life experience as close as possible to that of an individual without hemophilia. While existing guidelines provide recommendations for prophylaxis and on-demand treatment, they may not always fully address the nuances of lifestyle integration. For example, the WFH guidelines recommend prophylaxis to maintain trough levels above 1%, but achieving 'normalization' might require higher trough levels in some individuals to support high-impact activities. This is where shared decision-making and a thorough understanding of the patient's goals become paramount.

Practical Strategies for Normalization

So how do we translate this concept into actionable steps? Start by actively listening to your patients. What are their aspirations? What activities do they want to participate in? What limitations do they perceive? This information forms the foundation for a personalized treatment plan. This includes discussing target trough levels for factor replacement therapy, exploring extended half-life products, and considering emerging therapies like emicizumab or gene therapy where appropriate. Openly discuss the risks and benefits of each approach, acknowledging that the 'best' treatment is the one that aligns with the patient's individual needs and preferences. Counsel patients about practical strategies for managing bleeds in different settings, such as schools, workplaces, or during travel. Equip them with the knowledge and resources they need to confidently navigate these situations.

Addressing Activity Levels

Participation in sports and physical activity is a key component of 'normalization'. For children and adolescents, this might involve participating in team sports or recreational activities. For adults, it could mean engaging in fitness programs or

pursuing hobbies like hiking or cycling. The goal is to find activities that the patient enjoys and can safely participate in. This requires a careful assessment of bleeding risk and appropriate adjustments to the treatment regimen. For example, a patient who wants to play soccer might require higher factor levels or more frequent infusions than someone who prefers swimming. Discuss the use of protective gear, appropriate warm-up and cool-down routines, and strategies for managing minor injuries. Connect patients with resources like physical therapists or athletic trainers who have experience working with individuals with bleeding disorders. Remember, the goal is not to discourage activity but to enable it safely and effectively.

Psychosocial Well-being

Living with hemophilia can have a significant impact on psychosocial well-being. Chronic pain, anxiety about bleeding, and social stigma can all contribute to emotional distress. 'Normalization' also means addressing these challenges proactively. Screen patients for depression and anxiety, and provide referrals to mental health professionals as needed. Encourage participation in support groups or online communities where patients can connect with others who share similar experiences. Address issues related to body image and self-esteem, particularly in adolescents. Promote open communication within families and encourage parents to foster independence and self-advocacy in their children with hemophilia. Recognizing that the cost of hemophilia treatment can cause significant stress. Connect patients with financial assistance programs and resources to help them manage the economic burden of their condition.

Critique of the Normalization Concept

While 'normalization' represents a valuable shift in perspective, it is not without its limitations. The very definition of 'normal' is subjective and can vary significantly from person to person. Imposing a universal standard of 'normality' could inadvertently create unrealistic expectations or pressure patients to conform to a particular lifestyle. Furthermore, achieving 'normalization' may not always be feasible or desirable, particularly for individuals with severe hemophilia or those who have experienced significant joint damage. It's vital to acknowledge the individual's unique circumstances and tailor treatment goals accordingly. Access to comprehensive care, including specialized hemophilia treatment centers, remains a significant barrier for many patients, particularly those in rural or underserved areas. Additionally, the high cost of factor replacement therapy and emerging therapies can create significant financial challenges, limiting access to optimal treatment and hindering the pursuit of 'normalization'.

CLINICAL IMPLICATIONS

Adopting a 'normalization' approach requires a shift in clinical workflow. Longer appointment times may be needed to facilitate in-depth conversations about patient goals and lifestyle. Collaboration with other healthcare professionals, such as physical therapists, psychologists, and social workers, becomes essential. Clinicians also need to be aware of the financial implications of different treatment options and advocate for policies that ensure access to affordable care. Billing codes may need to be adjusted to reflect the increased complexity of patient-centered care. The long-term benefits of 'normalization', such as improved quality of life, reduced healthcare utilization, and increased patient adherence, justify the investment in this approach.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. World Federation of Hemophilia. (2020). Guidelines for the management of hemophilia (3rd ed.). Montreal, Canada.
2. National Hemophilia Foundation. (2012). The Medical and Scientific Advisory Council (MASAC) recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. New York, NY.
3. Srivastava, A., Brewer, A. K., Mauser-Bunschoten, E. P., Key, N. S., Kitchen, S., Llinás, A., ... & \aYCE À Trée (2013). Guidelines Working Group on behalf of the International Committee on Thrombosis and Haemostasis. Guidelines for the management of hemophilia. Haemophilia, 19(1), e1-e47.

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com